other
Eli Lilly's dual GIP/GLP-1 incretin drug, sold as Mounjaro for diabetes and Zepbound for obesity, used in weight-loss and sleep apnea research.
No evidence-backed relationships are recorded.
Japan's obesity society warned cosmetic GLP-1 users of side-effect risks, as 35 of about 950 Mounjaro side-effect reports involved dieting or cosmetic use. The health ministry separately said the drugs should not be used casually as weight-loss pills.
Reality
Retatrutide's 12 mg dose cut body weight 25% over 80 weeks, versus 3.9% on placebo, in a 2,339-adult phase 3 trial in NEJM. Its near-30% two-year figure comes from 532 completers, and because placebo was the only comparator, the trial cannot rank the drug against Ozempic.
Reality
Eli Lilly's 367-person trial found the top dose of tirzepatide plus eloralintide cut body weight 23.3%, against 14.8% on tirzepatide alone. Dropout ran far higher on the combination, so nobody has yet measured how much of that gain holds across everyone prescribed the pair.
Reality
Eli Lilly's retatrutide cut body weight by more than 20% on average at its top dose in an 80-week phase 3 trial of 1,152 people with type 2 diabetes. Lilly calls that a first for the field, and it gives the four- and five-receptor drugs now in development a figure to beat in patients with diabetes.
Reality
University of Barcelona researchers found that tirzepatide activated calorie-burning brown fat in obese mice eating the same amount as untreated controls. The result points to an effect on metabolism beyond appetite that has not yet been tested in humans.
Reality
Veterans with type 2 diabetes who came off semaglutide or tirzepatide lost most of the cardiovascular benefit within two years, and the benefit only appeared in patients who had stayed on the drug past 18 months.
Reality
The 2035 diversification target Novo gave investors in London is a single risk-adjusted total that includes assets already in the pipeline, and the launch list it published for 2027 through 2030 is almost all GLP-1 and amylin.
Reality
A Phase I dose-selection study put brenipatide's half-life at 9 to 12.5 days. Lilly says that supports once-weekly dosing in the Phase III trials it is now running in major depressive disorder and alcohol use disorder.
Reality
A University of Pennsylvania group read five years of GLP-1 discussion from nearly 70,000 Reddit users and came out with two symptom families worth a real study, plus a nausea signal that shows the method finds what is already known.
Reality
Semaglutide's approval starts above age 12 and tirzepatide's obesity approval at 18, but a published study and one Dallas hospital's own count both show children under 12 already taking these drugs, mostly for obesity and type 2 diabetes.
Reality
All three arms shed about a tenth of their body weight and improved muscle insulin sensitivity, so the separation showed up in the liver, where the keto arm cut fat and triglyceride production. Delivered meals bought the adherence that makes that readable.
Reality
Measured US adult obesity sat at 40.3 percent across 2013 to 2023 while severe obesity rose from 7.7 to 9.7 percent. The programs did not bend the line, and benefits committees now own the question.
Reality